Robert C Grant
Overview
Explore the profile of Robert C Grant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
2457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beaudry F, Li Z, Borgida A, Zorigtbaatar A, Wang X, Hildebrand M, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996880
Comprehensive molecular profiling can identify alterations in biliary tract cancer (BTC) potentially treatable with targeted therapies. However, the impact of whole-genome and transcriptome sequencing (WGTS) on therapeutic decision-making in a...
2.
Alduhayh S, Laskar R, Jiang X, Zhu Z, Vincent E, Constantinescu A, et al.
Cancer Epidemiol Biomarkers Prev
. 2025 Feb;
PMID: 39982694
Background: Tumor immunosurveillance theory supports that allergic conditions could decrease cancer risk. However, observational evidence yielded inconsistent results for the association between allergic diseases and colorectal cancer risk. We used...
3.
Alqaisi H, Cohn D, Chern J, Duska L, Jewell A, Corr B, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836408
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization...
4.
McHugh K, Pai R, Grant R, Gallinger S, Davison J, Ma C, et al.
Mod Pathol
. 2025 Jan;
38(5):100712.
PMID: 39826799
Claudin 18.2 (CLDN18.2) immunohistochemical (IHC) expression can be used to select patients with gastric/gastroesophageal junction adenocarcinomas for zolbetuximab (IMAB362) therapy, zolbetuximab (IMAB362) being a monoclonal antibody targeting CLDN18.2. The aim...
5.
Prizment A, Standafer A, Qu C, Beutel K, Wang S, Huang W, et al.
Hum Mol Genet
. 2025 Jan;
PMID: 39825500
Background: Individuals with cystic fibrosis (CF; a recessive disorder) have an increased risk of colorectal cancer (CRC). Evidence suggests individuals with a single CFTR variant may also have increased CRC...
6.
Walker R, Joo J, Mahmood K, Clendenning M, Como J, Preston S, et al.
Transl Oncol
. 2025 Jan;
52:102266.
PMID: 39793275
Background: Colorectal cancers (CRCs) from people with biallelic germline likely pathogenic/pathogenic variants in MUTYH or NTHL1 exhibit specific single base substitution (SBS) mutational signatures, namely combined SBS18 and SBS36 (SBS18+SBS36),...
7.
Thomas C, Takashima Y, Wesselink E, Ugai T, Steinfelder R, Buchanan D, et al.
Front Immunol
. 2025 Jan;
15:1505896.
PMID: 39763680
Background: Microsatellite instability-high (MSI-high) tumors comprise ~15% of sporadic colorectal cancers (CRC) and are associated with elevated T cell infiltration. However, the universality of this response across T cell subtypes...
8.
Magyar C, Perera S, Rajendran L, Li Z, Almugbel F, Feng S, et al.
Transplantation
. 2024 Nov;
PMID: 39531339
Background: Hepatocellular carcinoma (HCC) recurs after liver transplantation (LT) in ~17% of patients. We aimed to retrospectively compare the outcomes of patients treated with different tyrosine kinase inhibitors (TKIs) for...
9.
Fleshner L, Gandhi S, Lagree A, Boulard L, Grant R, Kiss A, et al.
JCO Clin Cancer Inform
. 2024 Oct;
8:e2400147.
PMID: 39475656
Purpose: Patients with cancer visit the emergency department (ED) frequently. While some ED visits are necessary, others may be potentially preventable ED visits (PPEDs). Reducing PPEDs is important to improve...
10.
Goodday S, Karlin E, Brooks A, Chapman C, Harry C, Lugo N, et al.
J Med Internet Res
. 2024 Sep;
26:e57827.
PMID: 39226552
Background: Wearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor....